Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
07/01/2026 14:49
Jan 7 (Reuters) - CERo Therapeutics Holdings Inc CERO.PK: CERO THERAPEUTICS PROVIDES CLINICAL UPDATE ON PHASE 1 TRIAL OF CER-1236 IN AML (CERTAINT-1) HIGHLIGHTING KEY SAFETY DATA AND PLATELET TRANSFUSION–FREE INTERVAL OBSERVED IN A PATIENT WITH MYELODYSPLASTIC SYNDROME/AML CERO THERAPEUTICS HOLDINGS INC - NO ADVERSE EVENTS REPORTED IN FIRST COHORT OF CERTAINT-1 TRIAL Source text: ID:nGNXGBYcL Further company coverage: CERO.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List